We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+24.01%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$280M
AUM Growth
+$43.5M
Cap. Flow
-$5.93M
Cap. Flow %
-2.12%
Top 10 Hldgs %
80.43%
Holding
20
New
3
Increased
1
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$10.6M
2
MCRB icon
Seres Therapeutics
MCRB
+$7.53M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$5.51M
4
VRDN icon
Viridian Therapeutics
VRDN
+$529K

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$9.81M
2
NGNE icon
Neurogene
NGNE
+$4.47M
3
INSM icon
Insmed
INSM
+$3.47M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$3.26M
5
FOLD
Amicus Therapeutics
FOLD
+$2.86M

Sector Composition

Rank Sector Weight
1 Healthcare 92.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.5B
$32M 11.45%
961,797
-95,000
-9% -$3.47M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$30.4M 10.86%
1,315,395
-140,000
-10% -$2.86M
IOVA icon
3
Iovance Biotherapeutics
IOVA
$2.23B
$26.3M 9.39%
565,890
-31,000
-5% -$1.23M
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.38B
$24.1M 8.61%
450,317
-197,516
-30% -$9.81M
TRIL
5
DELISTED
Trillium Therapeutics Inc.
TRIL
$21.7M 7.78%
1,478,181
-80,000
-5% -$1.15M
ALLK
6
DELISTED
Allakos
ALLK
$20.7M 7.39%
147,662
-17,000
-10% -$1.77M
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
$19.6M 7.01%
980,645
-76,230
-7% -$1.56M
AXSM icon
8
Axsome Therapeutics
AXSM
$11.8B
$17.9M 6.41%
220,098
– –
COGT icon
9
Cogent Biosciences
COGT
$6.68B
$17.5M 6.26%
1,558,975
-1
-0% -$11
ARGX icon
10
argenx
ARGX
$53.8B
$14.7M 5.25%
49,950
– –
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$13.3M 4.75%
60,500
+25,500
+73% +$5.51M
KPTI icon
12
Karyopharm Therapeutics
KPTI
$216M
$10.9M 3.89%
46,823
– –
GBT
13
DELISTED
Global Blood Therapeutics, Inc.
GBT
$9.31M 3.33%
+215,000
New +$10.6M
AMRN
14
Amarin Corp
AMRN
$292M
$7.38M 2.64%
75,412
– –
ENTA icon
15
Enanta Pharmaceuticals
ENTA
$400M
$6.33M 2.27%
150,433
-11,803
-7% -$519K
MCRB icon
16
Seres Therapeutics
MCRB
$51.6M
$6.3M 2.25%
+12,851
New +$7.53M
VRNA
17
DELISTED
Verona Pharma
VRNA
$700K 0.25%
100,000
– –
VRDN icon
18
Viridian Therapeutics
VRDN
$1.99B
$554K 0.2%
+35,092
New +$529K
KNSA icon
19
Kiniksa Pharmaceuticals
KNSA
$4.92B
– –
-212,746
Closed -$3.26M
NGNE icon
20
Neurogene
NGNE
$744M
– –
-18,637
Closed -$4.47M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q4 2020 Portfolio in Review

As of Q4 2020, Fairmount Funds Management held 20 positions worth $280M, up 18% from $236M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Fairmount Funds Management's Q4 2020 filing shows 3 new, 1 increased, 9 reduced and 2 closed positions. Its largest new stake was Global Blood Therapeutics, Inc.: 215,000 shares worth $9.31M. The largest sale was Acadia Pharmaceuticals, an estimated $9.81M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier.

  • Fairmount Funds Management's largest Q4 2020 buy was Global Blood Therapeutics, Inc.: 215,000 shares worth $9.31M.
  • Fairmount Funds Management added most to Mirati Therapeutics, Inc. Common Stock in Q4 2020, an estimated $5.51M increase.
  • Fairmount Funds Management's biggest Q4 2020 reduction was Acadia Pharmaceuticals, cutting an estimated $9.81M.
  • Fairmount Funds Management fully exited Neurogene in Q4 2020, selling an estimated $4.47M.
  • Fairmount Funds Management's ten largest holdings make up 80% of its $280M portfolio in Q4 2020.
  • Fairmount Funds Management opened 3 new positions and closed 2 in Q4 2020.
  • Fairmount Funds Management's portfolio value rose 18% quarter-over-quarter to $280M.

Based on Fairmount Funds Management's 13F filing for Q4 2020, filed 12 Feb 2021.